
    
      Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm
      B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib was
      administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days for a
      maximum of six cycles.
    
  